DOCSLIB.ORG

Fucidin H Cream Patient Leaflet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fucidin H Cream Patient Leaflet Scale Get-up Material No Sent by e-maiL l 100% GB 059516-XX Subject Date Date INS 175 x 280 mm 02/04/19 Colour Sign. Sign. Black RBE Preparation Place of production 213 Strength ® Packsize Fucidin H cream Ireland Comments: Page 1 of 2 Pharmacode 213 Font size: Heading: 9 pt, section: 8 pt, linespacing: 3 mm Mock-up for reg. purpose 175 mm IIE007-01 - 175 x 280 mm 175 x 280m Insert 100% PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin® H cream Fusidic acid and hydrocortisone acetate m Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. 20/01/2004 11/06/2018 IIE007-01 What is in this leaflet: Other medicines and Fucidin H cream 213 1. What Fucidin® H cream is and what it is used for Tell your doctor or pharmacist if you are taking, or have 2. Before you use Fucidin® H cream recently taken or might take any other medicines. 3. How to use Fucidin® H cream 4. Possible side effects Pregnancy and breast-feeding 5. How to store Fucidin® H cream Please ask your doctor or pharmacist for advice before 6. Contents of the pack and other information using Fucidin H cream: • If you are pregnant, or think you are pregnant. You 1. What Fucidin® H cream is and what it is used for must not use your medicine for a long time or in large OMA Fucidin H cream contains 2 different types of medicine. amounts. You must ask your doctor for advice. PSR One medicine is called fusidic acid. It is a type of • If you are breast-feeding. antibiotic. The other medicine is called hydrocortisone acetate. It is a type of corticosteroid (steroid). Tell your doctor if you become pregnant while using this medicine. These 2 medicines work at the same time in different ways. Used for: Isathalmic Fucibet Taclonex Dovonex Fucidin Calcipotriene. Conoptal Fucidin H cream works by: Driving and using machines • The antibiotic killing germs (bacteria) that cause infections. Usually your medicine will have very little effect on your 059516-XX • The corticosteroid reducing any swelling, redness or ability to drive or use machines. Check with your doctor if ® itchiness of your skin. you feel any side effect that may stop you from driving or ® , Fucidin , Fucithalmic ® using machines. ® , Daivobet , Psorcutan Fucidin H cream is used to treat: ® • Conditions where the skin is inflamed (eczema or Important information about some of the ingredients of , Verutex dermatitis) and also infected by germs (bacteria). Fucidin H cream Fucidin H cream contains: 2. What you need to know before you use • Butylhydroxyanisole (E320). This may give you an itchy ® ® H, Fucicort Fucidin H cream rash and inflammation on your skin where your medicine ® ® ® Do not use Fucidin H cream ® , Dovobet is used. This may also cause irritation to the eyes and , Verutex , Token , Isathal • If you are allergic (hypersensitive) to fusidic acid or mucous membranes (such as lips or genital area). ® hydrocortisone acetate. • Cetyl alcohol. This may give you an itchy rash and , Daivonex • If you are allergic (hypersensitive) to any of the other inflammation on your skin where your medicine is used. ingredients in your medicine. You can find a list of these • Potassium sorbate. This may give you an itchy rash and ® ® , ® ingredients in section 6 of this leaflet. , ® inflammation on your skin where your medicine is used. ® 280 mm • To treat a skin condition called acne rosacea. This is , B redness and inflammation over your nose and cheeks. Please ask your doctor if you are worried about any of the ® Ask your doctor if you are unsure. ingredients in this medicine. , • To treat a skin condition called perioral dermatitis. This ® is a red spotty rash around your mouth or chin. 3. How to use Fucidin H cream Comments: • To treat skin conditions caused by tuberculosis or syphilis. Always use Fucidin H cream exactly as your doctor has approved PackRat 1 column and 2 columns • To treat skin conditions caused only by bacteria, such as told you. Check with your doctor or pharmacist if you are boils or spots. not sure. • To treat a skin condition caused by a virus, such as cold How to put on Fucidin H cream sores or chickenpox. This medicine is only for using on your skin or the skin of • To treat a skin condition caused by a fungus, such as a child. Do not swallow it. Do not put it inside your body. athlete’s foot. Warnings and precautions Remove the cap. Check the seal is not broken before Talk to your doctor, pharmacist or nurse before using you first use the cream. Then push the spike in the cap Fucidin H cream through the seal on the tube. • Take special care if you are going to use this medicine Always wash your hands before using Fucidin H cream. near your eyes or the eyes of a child. If the cream gets Rub the medicine gently on the skin. If you use it on your into the eye, this may lead to glaucoma. face be careful to avoid your eyes. • Contact your doctor if you experience blurred vision or other visual disturbances. Unless you are using the cream to treat your hands, • If you use the cream over a long time or in large amounts always wash your hands after using Fucidin H cream. it may make the chance of getting any side effects higher. Also your skin may get more sensitive to this medicine. If you accidentally get any medicine in your eye, wash it • You must not use the medicine for a long time on your out with cold water straight away. Then bathe your eye face. with eyewash if possible. Your eye may sting. If you start to have any problems with your sight or your eye is sore, • Unless your doctor has told you to, you must not use info: Revision contact your doctor immediately. Fucidin H cream on open wounds or sensitive areas changed reference from INS005 to IIE005-01 IIE007-01 INS007-00 - 22/09/2017 DVR Moved details about itemnumber such as the nostrils, ears, lips or genitals. How much Fucidin H cream to use • Unless your doctor has told you to, you must not use Your doctor will tell you how much Fucidin H cream to use. Fucidin H cream on thin skin, skin ulcers, broken veins or acne. The usual treatment time is up to 2 weeks. Ask your • Adrenal suppression may occur. Signs are tiredness, doctor before using this medicine for any longer. depression and anxiety. This can be reversed by - stopping Fucidin H cream. You should notice your skin improve after just a few 03/06/2018 - OMA Updated for CI project (CAPA 173674), • Treatment should be stopped after 7 days if your skin days of using the cream. If there is no improvement after has not improved after using Fucidin H cream. 7 days you should stop using the cream and go back to your doctor. Do not smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has Usually, you should use this medicine twice each day. been in contact with this product burns more easily and is Use it in the morning and evening. To remind you to use a serious fire hazard. Washing clothing and bedding may the medicine it may help to use it when you do another reduce product build-up but not totally remove it. regular action, such as brushing your teeth. 4. RBE 01/10/19 SOP_000647, SOP_000962, SOP_000647, SOP_000962 SOP_003993 and and SOP_008676 SOP_008676 Scale Get-up Material No Sent by e-maiL l 100% GB 059516-XX Subject Date Date INS 175 x 280 mm 02/04/19 Colour Sign. Sign. Black RBE Preparation Place of production Strength ® Packsize Fucidin H cream Ireland Comments: Page 2 of 2 Mock-up for reg. purpose 175 mm IIE007-01 - 175 x 280 mm 175 x 280m Insert 100% If you have been told to cover the skin with any dressings Skin problems or bandages you may not need to use the medicine so Common side effects (may affect up to 1 in 10 people) often. A nappy on a baby may act as a dressing. Follow • Application site reaction (including itching, burning and the advice of your doctor. irritation). Adults and children: Uncommon side effects (may affect up to 1 in 100 people) m Your doctor should tell you the dose that is right for you or • Itchy rash and skin inflammation in the area where the the child. If your doctor has told you the amount of cream medicine is used to use then keep to this advice. If not, the following guide • Worsening of your eczema will help you to use the correct amount. • Skin rash. You can use your first (index) finger to measure how Frequency not known (cannot be estimated from the much Fucidin H cream to use. Squeeze the cream along available data) your finger from the tip to the first joint as shown in the • Blurred vision.
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Acute-Onset Alopecia
    PHOTO CHALLENGE Acute-Onset Alopecia Justin P. Bandino, MD; Dirk M. Elston, MD A previously healthy 45-year-old man presented to the dermatology department with abrupt onset of patchy, progressively worsening alopecia of the scalp as well as nausea with emesis and blurry vision of a few weeks’ duration. All symptoms were temporally associated with a new demoli- tion job the patient had started at an industrial site. He reportedcopy 10 other contractors were simi- larly affected. The patient denied paresthesia or other skin changes. On physical examination, large patches of smooth alopecia without ery- thema,not scale, scarring, tenderness, or edema that coalesced to involve the majority of the scalp, eye- brows, and eyelashes (inset) were noted. Do WHAT’S THE DIAGNOSIS? a. alopecia areata b. dioxin-induced alopecia c. phosgene-induced alopecia d. syphilitic alopecia CUTIS e. thallium-induced alopecia PLEASE TURN TO PAGE E25 FOR THE DIAGNOSIS From the Department of Dermatology, Medical University of South Carolina, Charleston. The authors report no conflict of interest. Correspondence: Justin P. Bandino, MD, 171 Ashley Ave, MSC 908, Charleston, SC 29425 ([email protected]). E24 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2019. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Thallium-Induced Alopecia t the time of presentation, a punch biopsy speci- pencil point–shaped fractures that shed approximately men of the scalp revealed nonscarring alopecia 1 to 2 months after injury. The 10% of scalp hairs in A with increased catagen hairs; follicular minia- the resting telogen phase have no matrix and thus are turization; peribulbar lymphoid infiltrates; and fibrous unaffected.
    [Show full text]
  • Dovobet Gel Patient Information Leaflet
    L Scale Get-up Material No Sent by e-maiL l Scale Get-up Material No Sent by e-mail 100% Used for: GB 000000-XXComments: Insert, 2 columns Page 1 IIE015-02Subject Daivobet®, Dovobet®, Xamiol ® Date gel. SpaceDate for text: 2 X 67,5 x 580 mm. Subject Date Date INS 160 x 600 mm 05/05/20 Colour Sign. MaterialSign. number must be printed on both sides Colour Sign. Sign. 160 x 600 mm 08/09/2010 JUG Black RBE Material number on page 1, OCRB 8pt kerning+10(Quark)/ Preparation 100% 08/06/2018 OMA Place of productionOCRB MEDIUM 8pt kerning+50(Indesign) Preparation Place of production Strength ® Strength Packsize Dovobet gel Ireland Packsize Ireland Comments: Comments: Page 1 of 2 Font size: 9 pt Mock-up for reg. purpose 160 mm IIE015-02 - 160 x 600 mm - Page 1 of 2 2. 05/05/20 Package leaflet: Information for the user Dovobet® 50 micrograms/g + 0.5 mg/g gel RBE calcipotriol/betamethasone SOP_00867 SOP_003993 and SOP_000647, SOP_000962 Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. 6 • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
    [Show full text]
  • PSORCON® E Emollient Ointment (Diflorasone Diacetate Ointment) 0.05%
    PSORCON® E Emollient Ointment (diflorasone diacetate ointment) 0.05% For Topical Use Not For Ophthalmic Use DESCRIPTION Each gram of Psorcon E Emollient Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is: 6α,9-difluoro-11β,17,21-trihydroxy- 16β-methyl-pregna-1,4-diene-3,20-dione 17,21-diacetate. The structural formula is represented below: Psorcon E Emollient Ointment contains diflorasone diacetate in an emollient, occlusive base consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum. CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, 1 occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and are then excreted by the kidneys.
    [Show full text]
  • Dermatology Dr Matt Smialowski GP, Tunbridge Wells Introduction
    Dermatology Dr Matt Smialowski GP, Tunbridge Wells Introduction . Overview of General Practice Dermatology . Based on curriculum matrix . Images from dermnet.nz . Management from dermnet.nz and NICE CKS . Focus on the common presenting complaints and overview of treatments . Quiz and Questions Dermatology Vocabulary . Useful to be able to describe the problem in notes / referrals . Configuration . Nummular / discoid: round or coin-shaped . Linear: often occurs due external factors (scratching) . Target: concentric rings . Annular: lesions grouped in a circle. Serpiginous: snake like . Reticulate: net-like with spaces Dermatology Vocabulary . Morphology . Macule: small area of skin 5-10mm, altered colour, not elevated . Patch: larger area of colour change, with smooth surface . Papule: elevated, solid, palpable <1cm diameter . Nodule: elevated, solid, palpable >1cm diameter . Cyst: papule or nodule that contains fluid / semi-fluid material . Plaque: circumscribed, palpable lesion >1cm diameter . Vesicle: small blister <1cm diameter that contains liquid . Pustule: circumscribed lesion containing pus (not always infected) . Bulla: Large blister >1cm diameter that contains fluid . Weal: transient elevation of the skin due to dermal oedema Skin Function . Prevention of water loss . Immune defence . Protection against UV damage . Temperature regulation . Synthesis of vitamin D . Sensation . Aesthetics Skin Structure Eczematous Eruptions Cheilitis / Peri-oral Dermatitis . Common problem . Acute / relapsing / recurrent . Causes . Chelitis . Environmental: sun damage . Inflammatory . Angular cheilits . Infection: fungal . Vitamin B / iron deficiency . Perioral dermatitis . Potent topical steroids Pompholyx . Vesicular form of hand or foot eczema. Commonly affects young adults. Causes . Sweating . Irritants . Recurrent crops of itchy deep-seated blisters. Pompholyx . General Measures . Cold packs . Soothing emollients . Gloves / avoid allergens . Prescription: . Potent topical steroids . Oral steroids .
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Pediatric Periorificial Dermatitis
    PEDIATRIC DERMATOLOGY Pediatric Periorificial Dermatitis Roselyn Kellen, BA; Nanette B. Silverberg, MD symptoms unless patients have comorbid conditions such 5 PRACTICE POINTS as atopic dermatitis. Although this condition has been • Periorificial dermatitis (POD) affects young children well examined in the literature on adults, data in the pedi- and presents as flesh-colored papules around the atric population are far more limited, consisting of case mouth, nose, and even groin. series and retrospective chart reviews. In 1979, Wilkinson 6 • Periorificial dermatitis has been associated with prior et al published a study of more than 200 patients with use of topical or inhaled steroids. perioral dermatitis, but only 15 patients younger than • Children with POD can be treated with oral erythromycin. 12 years were included. Etiology copy Although the exact pathogenesis of POD is unknown, Periorificial dermatitis (POD) has been documented in the pediatric a common denominator among many patients is prior population in patients as young as 3 months, with a slight predomi- exposure to topical corticosteroids.3,7-9 Periorificial der- nance in girls compared to boys. Many patients have a personal or matitis also has been linked to the use of systemic cor- family history of atopic disorders. Periorificial dermatitis typically ticosteroidsnot in pediatric patients.10 The exact relationship presents with erythematous to flesh-colored papules and rarely between steroid use and dermatitis is unknown; it may pustules near the eyes, nose, and mouth. Although the etiology be related to a change in the flora of hair follicles and is unknown, many patients have had recent exposure to a topical or less commonly an inhaled or systemic corticosteroid.
    [Show full text]
  • “The Red Face” and More Clinical Pearls
    “The Red Face” and More Clinical Pearls Courtney R. Schadt, MD, FAAD Assistant Professor Residency Program Director University of Louisville Associates in Dermatology I have no disclosures or conflicts of interest Part 1: The Red Face: Objectives • Distinguish and diagnose common eruptions of the face • Recognize those with potential implications for internal disease • Learn basic treatment options Which patient(s) has an increased risk of hypertension and hyperlipidemia? A B C Which patient(s) has an increased risk of hypertension and hyperlipidemia? A Seborrheic Dermatitis B C Psoriasis Seborrheic Dermatitis Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott Williams & Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams & Wilkins. Seborrheic Dermatitis • Erythematous scaly eruption • Infants= “Cradle Cap” • Reappear in adolescence or later in life • Chronic, remissions and flares; worse with stress, cold weather • Occurs on areas of body with increased sebaceous glands • Unclear role of Malassezia; could be immune response; no evidence of overgrowth Seborrheic Dermatitis Severe Seb Derm: THINK: • HIV (can also be more diffuse on trunk) • Parkinson’s (seb derm improves with L-dopa therapy) • Other neurologic disorders • Neuroleptic agents • Unclear etiology 5MinuteClinicalConsult Clinical Exam • Erythema/fine scale • Scalp • Ears • Nasolabial folds • Beard/hair bearing areas Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott • Ill-defined Williams & Wilkins, Philadelphia
    [Show full text]
  • Dermatologic Therapeutics: Bread and Butter and Beyond
    Dermatologic Therapeutics: Bread and Butter and Beyond Bonnie Mackool, MD, MSPH Assistant Professor of Dermatology, Harvard Medical School Massachusetts General Hospital Disclosures Neither I nor my spouse/partner has a relevant financial relationship with a commercial interest to disclose. Medication Overview: Anti-microbial Anti-inflammatory Anti-histaminic Anti-neoplastic Retinoids Biologics Immunosuppressive Hormonal Therapy Systemic Agents Topical Agents Balneotherapy Cryotherapy Phototherapy Laser Radiation Surgical Dermatologic Medical Armamentarium Includes: • Adapalene (Differin) cream/gel • Cyclosporine (Neoral) • Azelaic acid (Azelex) cream • Adalimumab (Humira) • Topical steroids • Etanercept (Enbrel) • Tetracycline • Intravenous Immunoglobulin IVIG • Minocycline • Doxycycline • Anthralin (Drithrocream) • Dapsone (Aczone) gel • Mupirocin (Bactroban)ointment • Benzoyl peroxide + clinda or erythro • Tacrolimus ointment • Finasteride (Propecia) • Pimecrolimus cream • Tazarotene • Metronidazole (Metrocream/gel) • Tretinoin cream • Hydroxyzine (Atarax) • Methotrexate • Tri-Luma cream (tret, hydroquinone, ster) • Sodium thiosulfate IV • Hydroxychloroquine • Mycophenolate mofetil (cellcept) • Chloroquine • Azathioprine (Imuran) Dermatologic Medical Armamentarium (cont.): • Spironolactone • Calcipotriene (Dovonex) oint/cr • Isotretinoin (Accutane) • Acyclovir (Zovirax) tabs/oint/cr • 5 Fluorouracil (Efudex) cream/solution • Naltrexone • Imiquimod (Aldara) cream • Gabapentin (Neurontin) • Rituximab (Rituxan) • Doxepin Hydrochloride
    [Show full text]
  • Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature
    CONTINUING MEDICAL EDUCATION Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature Amy Y-Y Chen, MD; Matthew J. Zirwas, MD RELEASE DATE: April 2009 TERMINATION DATE: April 2010 The estimated time to complete this activity is 1 hour. GOAL To understand steroid-induced rosacealike dermatitis (SIRD) to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Explain the clinical features of SIRD, including the 3 subtypes. 2. Evaluate the multifactorial pathogenesis of SIRD. 3. Recognize the importance of a detailed patient history and physical examination to diagnose SIRD. INTENDED AUDIENCE This CME activity is designed for dermatologists and generalists. CME Test and Instructions on page 195. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. March 2009. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 Credit TM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Dr. Chen owns stock in Merck & Co, Inc. Dr. Zirwas is a consultant for Coria Laboratories, Ltd, and is on the speakers bureau for Astellas Pharma, Inc, and Coria Laboratories, Ltd.
    [Show full text]
  • Dermatology Update
    12/6/19 Dermatology Update Lindy P. Fox, MD Professor of Clinical Dermatology Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco [email protected] I have no conflicts of interest to disclose I may be discussing off-label use of medications 1 1 Outline • Principles of topical therapy • Chronic Urticaria • Alopecia • Acne in the adult • Perioral dermatitis • Sunscreens 2 2 1 12/6/19 Principles of Dermatologic Therapy Moisturizers and Gentle Skin Care • Moisturizers – Contain oil to seal the surface of the skin and replace the damaged water barrier – Petrolatum (Vaseline) is the premier and “gold standard” moisturizer – Additions: water, glycerin, mineral oil, lanolin – Some try to mimic naturally occurring ceramides (E.g. CeraVe) • Thick creams more moisturizing than pump lotions 3 Principles of Dermatologic Therapy Moisturizers and Gentle Skin Care • Emolliate skin – All dry skin itches • Gentle skin care – Soap to armpits, groin, scalp only – Short cool showers or tub soak for 15-20 minutes – Apply medications and moisturizer within 3 minutes of bathing or swimming 4 2 12/6/19 Principles of Dermatologic Therapy Topical Medications • The efficacy of any topical medication is related to: 1. The concentration of the medication 2. The vehicle 3. The active ingredient (inherent strength) 4. Anatomic location 5 Vehicles • Ointment (like Vaseline): – Greasy, moisturizing, messy, most effective. • Creams (vanish when rubbed in): – Less greasy, can sting, more likely to cause allergy (preservatives/fragrances).
    [Show full text]
  • Extrafacial and Generalized Granulomatous Periorificial Dermatitis
    OBSERVATION Extrafacial and Generalized Granulomatous Periorificial Dermatitis Amy J. Urbatsch, MD; Ilona Frieden, MD; Mary L. Williams, MD; Boni E. Elewski, MD; Anthony J. Mancini, MD; Amy S. Paller, MD Background: Granulomatous periorificial dermatitis is limiting, and were not associated with systemic involve- a well-recognized entity presenting most commonly in ment. Resolution seemed to be hastened with the use of prepubertal children as yellow-brown papules limited to systemic antibiotic therapy in 4 of the 5 patients. the perioral, perinasal, and periocular regions. The con- dition is self-limiting and is not associated with sys- Conclusions: Extrafacial lesions can occur in granulo- temic involvement. matous periorificial dermatitis and do not appear to ad- versely affect the duration, response to therapy, or risk Observations: We reviewed the medical charts of 5 of extracutaneous manifestations. Overly aggressive evalu- healthy children presenting with extrafacial granuloma- ation and inappropriate systemic therapy should be tous papules in addition to the typical periorificial avoided. papules. These extrafacial lesions were clinically and histologically identical to the facial lesions, were self- Arch Dermatol. 2002;138:1354-1358 1 N 1970, Gianotti et al described REPORT OF CASES 5 children with monomorphic perioral papules that showed a CASE 1 granulomatous pattern when le- sional biopsy sections were ex- A 23-month-old white boy with no history Iamined. Since then, several additional pa- of skin disease developed lesions
    [Show full text]